In today’s briefing:
- Tokyo Electron (8035 JP): MAGIC Versus Reality
- Deep Dive: Japanese Trading Companies (Part 1)
- Bajaj Finance: Leveraging Its Platform to Deepen and Widen Its Product Penetration
- China Healthcare Weekly (Feb.10) – Assisted Reproduction into NRDL, Cell Therapy, Medicilon, IRay,
- Lululemon: Ignore The Margin Compression Talk
- Electronic Arts (EA): Collaboration With Marvel Entertainment & Other Drivers
- Sysco Corporation: Major Drivers
- Equinor: Dividends Rising At The Norwegian Energy Major After 75% Price Gains
- Bill.com Holdings: Major Drivers
- Amgen Inc: Acquisition Of Horizon Therapeutics & Other Drivers
Tokyo Electron (8035 JP): MAGIC Versus Reality
- The market welcomed TEL’s 3Q results and new guidance, but sales, profits and margins continue to decline year-on-year.
- An optimistic consensus sees a new cyclical high in the second half of the decade, but avoids the question of disengagement from China.
- Inventories are at a record high. Valuations out to FY Mar-25 do not look attractive.
Deep Dive: Japanese Trading Companies (Part 1)
This is Part 1 of our exclusive deep dive on “Sogo Shosha”, or Japanese trading companies.
We’ve decided to break this deep dive into two parts given its length.
Part 1 will build the foundation and covers the business, history, and a discussion of Berkshire’s investment.
Bajaj Finance: Leveraging Its Platform to Deepen and Widen Its Product Penetration
- Bajaj Finance Ltd (BAF IN) reported decent profitability. Growth was somewhat muted due to competition, however, this seems temporary.
- The immediate focus of BAF to drive the next leg of growth is to deepen its product penetration across its existing branches. Currently, only 3% branches have 80%+ products.
- BAF revealed its long-term strategic plan wherein it plans to enter into newer categories like Auto, Agri, and CV which comprise 28% of the Indian retail credit market.
China Healthcare Weekly (Feb.10) – Assisted Reproduction into NRDL, Cell Therapy, Medicilon, IRay,
- The benefits of assisted reproduction being covered by medical insurance are limited. Its main role is still to delay not fundamentally reverse the decline of China’s birth rate.
- If the valuation collapse occurs collectively in one field, it basically reflects that Miss Market does not hold much hope for this field in the future, such as cell therapy.
- We mainly analyzed some key points of the companies that investors may be interested in, such as iRay Technology (688301 CH) and Shanghai Medicilon Inc (688202 CH).
Lululemon: Ignore The Margin Compression Talk
- Lululemon Athletica Inc.’s calendar year margin compression is due to variable costs that will probably adjust lower this year.
- Many analysts mistake’monetized costs’ such as excess amortization for cash costs.
- Lululemon Athletica Inc. (NASDAQ:LULU) stock has surged by nearly 2000% since its initial public offering in 2007.
Electronic Arts (EA): Collaboration With Marvel Entertainment & Other Drivers
- Electronic Arts delivered a mixed set of results in the last quarter.
- In the quarter more than 10 million new players entered into the community which drives strong engagement.
- The player network of EA also continues to grow and its flagship, EA SPORTS FIFA delivered strong engagement this quarter across the company’s entire ecosystem.
Sysco Corporation: Major Drivers
- Sysco delivered a mixed set of results for the last quarter and it was able to surpass the analyst consensus estimate in terms of revenues as result of double-digit sales growth.
- However, despite a decent earnings growth year-over-year and strong volume growth as well as market share gains, the company missed out on meeting earnings expectations.
- Sysco continues to advance its growth strategy with progress in its digital tools, merchandising initiatives, and supply chain investments in sales.
Equinor: Dividends Rising At The Norwegian Energy Major After 75% Price Gains
- Equinor rose 75% over the three-year period but has stalled.
- European gas prices may be nearing a bottom, according to the company.
- The company’s 10-year outlook looks good after record profits this quarter. It has been offered as an alternative to U.S.
Bill.com Holdings: Major Drivers
- Bill.com generated decent second-quarter result with revenues beyond market expectations and narrower-than-expected losses.
- Its extensive and expanding partner and network ecosystem offered a competitive advantage by allowing them to access new firms efficiently.
- With the joint objective of generating additional value for SMBs, they collaborate with an SMB’s most reliable advisors, including their accounting firms and financial institutions.
Amgen Inc: Acquisition Of Horizon Therapeutics & Other Drivers
- The company carried out some major acquisitions in the year including the $3.7 billion purchase of ChemoCentryx followed by the even bigger, $27.8 billion acquisition of Horizon Therapeutics.
- Their portfolio will also grow due to the addition of Horizon Therapeutics.
- In this report, we have carried out a fundamental analysis of the historical financial statements of the company.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars